Alliance Global Partners analyst James Molloy lowered the firm’s price target on Soligenix (SNGX) to $6 from $10 and keeps a Buy rating on the shares after the company reported recent corporate updates and clinical progress of HyBryte. The firm says its price target represents a sum-of-the-parts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX: